LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

Search

Alkermes PLC

Geschlossen

BrancheGesundheitswesen

50.18 4.32

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

47.88

Max

51.57

Schlüsselkennzahlen

By Trading Economics

Einkommen

-116M

-66M

Verkäufe

8.4M

393M

KGV

Branchendurchschnitt

51.133

50.958

EPS

0.38

Gewinnspanne

-16.92

Angestellte

2,050

EBITDA

-98M

-22M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+4.01% upside

Dividenden

By Acuity

Nächstes Ergebnis

28. Juli 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

2B

7.7B

Vorheriger Eröffnungskurs

45.86

Vorheriger Schlusskurs

50.18

Nachrichtenstimmung

By Acuity

10%

90%

13 / 342 Ranking in Healthcare

Alkermes PLC Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Über Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
help-icon Live chat